Anti-Sense Video
PEACHBRAIN!
cutie!
?
cutie!
?
| AntisenseTherapeutics.com - The Antisense Resource | |||
Anti-Sense Video
PEACHBRAIN!
Comments on "Anti-Sense" cutie!
?
|
Recent Police Force News: Related Videos: Lanoderm from Isis pharma.flv www.natural-biocare.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>Palomar - Let's Talk Plans Palomar - Let's Talk Plans. This track has really grown on me. Dale should do a video for it!TEEN DERM from ISISPHARMA
natural-herbs-market.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>
Global Rheumatoid Arthritis Therapeutics Market to Exceed $23.12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligon
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
Arrowhead Releases New Report Assessing State of Personalized Medicine Market
Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Scholarship Honours York University Chemistry Professor
Global Prostate Cancer Therapeutics Market to Reach $4.8 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
antisensedrugs.com
adultstemcell.org
|
||